<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0119775</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-25354</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lack of an Association between Angiotensin Receptor Blocker Based Therapy and Increased Risk of Cancer: Evidence from Large Observational Studies</article-title>
<alt-title alt-title-type="running-head">ARB-Based Therapy and Risk of Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yang</surname>
<given-names>Yuan</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Fan</given-names>
</name>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Skrip</surname>
<given-names>Laura</given-names>
</name>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lei</surname>
<given-names>Han</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Luo</surname>
<given-names>Suxin</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lu</surname>
<given-names>Kai</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Hu</surname>
<given-names>Dayi</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Cardiovascular Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>School of Public Health and Health Management, Chongqing Medical University, Chongqing, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Behrens</surname>
<given-names>Thomas</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Universität Bochum, GERMANY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: DH YY. Performed the experiments: YY FZ LS. Analyzed the data: YY FZ LS HL. Contributed reagents/materials/analysis tools: HL SL KL. Wrote the paper: YY FZ LS DH SL KL.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ebm_cq@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>3</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<elocation-id>e0119775</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>8</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>2</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Yang et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0119775" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>A previous meta-analysis of randomized controlled studies that were not designed to investigate cancer as a primary outcome suggested that ARB-based therapy is associated with increased risk of cancer; however, results of recent observational studies considering the association have been contradictory. This study sought to evaluate the association between angiotensin receptor blocker (ARB)-based therapy and risk of cancer by conducting a meta-analysis of observational studies.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Relevant articles published before February 2014 were identified by searching PubMed and the Cochrane Library. Pooled relative risks (RRs) were determined using a random effects model and were used to assess the strength of association between use of ARB-based therapy and risk of cancer.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Six retrospective cohort studies involving a total of 3,827,109 participants and four case-control studies involving a total of 193,029 cases were included. The present study found that ARB-based therapy was not significantly associated with an increased risk of cancer (RR = 0.87, 95%CI: [0.75, 1.01]). However, an analysis including only cohort studies suggested a significantly decreased risk of cancer among individuals with any history of ARB use as compared to those with no history of ARB use (RR = 0.80, 95%CI: [0.55, 0.95]); no significant association was found between ARB use and risk of cancer when the case-control studies were separately considered (RR = 1.03, 95%CI: [0.93, 1.13]). Subgroup analyses showed that use of ARB-based therapy was associated with decreased risk of lung cancer (RR = 0.81, 95%CI: [0.69, 0.94]); however, no significant associations were found with the other cancer sites investigated. Furthermore, no association was observed upon adjustment by type of ARB drug. No publication bias was detected.</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>Overall, ARB-based therapy was not associated with increased risk of cancer. However, its use may be related to decreased incidence of lung cancer; this finding should be considered carefully and confirmed with further studies.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The work was supported by National Key Clinical Specialties Construction Program of China.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<page-count count="14"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Angiotensin receptor blockers (ARBs) serve as first-line treatment for patients with hypertension. The potential relationship between ARB use and risk of cancer has been studied widely, although associations between increased risk and administration of ARBs as monotherapy have been modest or non-significant [<xref rid="pone.0119775.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0119775.ref002" ref-type="bibr">2</xref>]. A 2010 meta-analysis of eight randomized controlled trials (RCTs) provided evidence that ARB-based therapy was associated with slightly, yet significantly increased incidence of cancer (relative risk (RR): 1.08; 95% confidence interval (CI): [1.01, 1.15]) [<xref rid="pone.0119775.ref001" ref-type="bibr">1</xref>]. However, a subsequent meta-analysis of 70 RCTs found no association between ARBs as monotherapy and increased risk of cancer [<xref rid="pone.0119775.ref002" ref-type="bibr">2</xref>].</p>
<p>ARBs act on the renin-angiotensin-aldosterone system. Angiotensin II is the main mediator in the renin-angiotensin system (RAS), which is generated by the activation of angiotensin I through the angiotensin converting enzyme. However, angiotensin II is not only an effective hypertensive agent, but also is related to cell growth [<xref rid="pone.0119775.ref003" ref-type="bibr">3</xref>–<xref rid="pone.0119775.ref009" ref-type="bibr">9</xref>]. Expression of RAS mediators has therefore been demonstrated in cancer tissues [<xref rid="pone.0119775.ref010" ref-type="bibr">10</xref>]. There are several potential mechanisms for the involvement of ARBs in carcinogenesis at specific sites. For instance, in vitro, telmisartan has been shown to inhibit human urological cancer cell growth through early apoptosis by peroxisome proliferator-activated receptor (PPAR)-γ [<xref rid="pone.0119775.ref011" ref-type="bibr">11</xref>], which provides a strong link between lipid metabolism and the regulation of gene transcription [<xref rid="pone.0119775.ref012" ref-type="bibr">12</xref>]. In hormone-refractory prostate cancer cells, ARBs have been observed to inhibit angiogenesis by transcriptional factor Ets-1 which regulates angiotensin II-mediated vascular pathophysiology [<xref rid="pone.0119775.ref003" ref-type="bibr">3</xref>] and genes involved in endothelial function and angiogenesis [<xref rid="pone.0119775.ref004" ref-type="bibr">4</xref>]; ARBs have likewise been shown to inhibit angiogenesis by hypoxia inducible factor-1 alpha (HIF-1a) which plays a role in vascular endothelial growth factor (VEGF) induction by angiotensin II in vascular smooth muscle cells (VSMC) [<xref rid="pone.0119775.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0119775.ref006" ref-type="bibr">6</xref>]. Furthermore, local angiotensin II generation has been demonstrated in human gastric cancer, with tumor progression facilitated through the activation of ERK1/2 and NF-kappa B [<xref rid="pone.0119775.ref007" ref-type="bibr">7</xref>]. For lung cancer, Batra et al [<xref rid="pone.0119775.ref013" ref-type="bibr">13</xref>] found that angiotensin II elevated cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. Lastly, Gallagher [<xref rid="pone.0119775.ref014" ref-type="bibr">14</xref>] suggested that Ang-(1–7) inhibited the lung cancer cell growth through the activation of an angiotensin peptide receptor and may represent a novel chemotherapeutic and chemopreventive treatment for lung cancer.</p>
<p>Since the publication of both meta-analyses and laboratory researches results, large observational studies investigating the potential association between ARB use and risk of cancer have been widely conducted [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>]. Many of these studies have methodologically extended beyond the RCTs included in the 2010 meta-analyses in that they use cancer as the primary outcome and they considered risk for specific cancer sites [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0119775.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>]. In response to this recent accumulation of evidence, we sought to evaluate the association between ARB-based therapy and risk of cancer by conducting a meta-analysis of large cohort and case-control studies.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Search strategy</title>
<p>Relevant studies were identified through PubMed and the Cochrane Library databases by using the following search terms: 1) Cancer: “cancer” OR “carcinoma” OR “malignancy” OR “neoplasm” OR “tumor”; 2) ARB drugs: “angiotensin-receptor blocker” OR “ARB” OR “losartan” OR “valsartan” OR “candesartan” OR “irbesartan” OR “eprosartan” OR “telmisartan” OR “olmesartan”; and 3) Study design: “cohort studies” OR “follow-up studies” OR “prospective studies” OR “cross-sectional studies” OR “longitudinal studies” OR “retrospective studies” OR “case control studies”. Additionally, the reference lists of articles retrieved from databases, conference abstracts, and the publication lists of experts on ARB therapy were reviewed for other possible studies. This search strategy was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement [<xref rid="pone.0119775.ref025" ref-type="bibr">25</xref>] and all studies ultimately included in the analysis had been published on or before Feb 25, 2014.</p>
</sec>
<sec id="sec008">
<title>Selection criteria</title>
<p>Based on a review of the retrieved articles’ titles/abstracts and full texts, studies were chosen if they met all of the following criteria: (i) the study was designed as a prospective or retrospective cohort study or as a case control study; (ii) the primary exposure investigated was patients’ use of ARB-based therapy, and the primary outcome was the incidence of cancer; (iii) the articles provided hazard rate (HR) or relative risk (RR) estimates and the corresponding 95% confidence intervals (CIs), the size of the baseline samples, the total number of cases, the total number of years of follow up, and confounders for adjustment; (iv) when multiple publications reported on the same study, the most recent article was selected; (v) the publication language was limited to English and Chinese; (iv) the randomized controlled trials were excluded.</p>
</sec>
<sec id="sec009">
<title>Data extraction</title>
<p>The following information was extracted independently by two authors (Yang Y and Zhang F) from each article: first author, year of publication, study location, subject ethnicity, study period, duration of follow-up, source population, mean sample age at baseline, number of cases, assessment of ARB-based therapy use, ascertainment of cases, adjustment for covariates, hazard ratio (HR) or relative risk (RR), and the corresponding 95% confidence interval.</p>
</sec>
<sec id="sec010">
<title>Assessment of Study Quality</title>
<p>Study quality was scored using the Newcastle-Ottawa-Scale (NOS). The NOS was developed for quality assessment of non-randomized observational studies such as those included in the current meta-analysis. Details on the NOS “star system” can be found elsewhere [<xref rid="pone.0119775.ref026" ref-type="bibr">26</xref>]. Scoring for quality assessment was independently conducted by two authors (Yang Y, Zhang F); their results were compared and a third party (Hu D) intervened if consensus could not be reached.</p>
</sec>
<sec id="sec011">
<title>Statistical analyses</title>
<p>Relative risk (RR) estimates were used to measure the association between ARB-based therapy and risk of cancer. The hazard ratio was considered as a RR for the present analysis. One study [<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>] reported hazard ratios separately for colon and rectal cancers; using the method reported by Hamling [<xref rid="pone.0119775.ref027" ref-type="bibr">27</xref>], we combined the results for these two sites for subgroup analysis of colorectal cancer.</p>
<p>Inter-study heterogeneity was assessed using the Cochran’s <italic>χ</italic><sup>2</sup>-based Q test and the I-squared test [<xref rid="pone.0119775.ref028" ref-type="bibr">28</xref>]. If no significant heterogeneity (defined as <italic>P</italic>&gt;0.10 or I<sup>2</sup> &lt;50%) was found, the pooled RR estimate was determined with the fixed effects model (Mantel-Haenszel); the random effects model (DerSimonian and Laird) was used in the case of significant heterogeneity [<xref rid="pone.0119775.ref029" ref-type="bibr">29</xref>]. Stratification analyses by study design, ethnicity, cancer site, and type of ARB drug were conducted as a way of addressing inter-study heterogeneity. Further more, meta-regression was also conducted when necessary.</p>
<p>To consider particular study elements that could impact the overall findings, the sensitivity analyses were conducted by excluding studies with the following characteristics. Accordingly, we considered the change of results upon removal of (i) studies that had follow up of less than four years; (ii) studies with less than 2000 cases; (iii) studies with NOS scores less than 7; (iv) studies adjusted with insufficient confounders (less than 3 confounders) [<xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>], or no adjustments [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>]; and (v) studies that had users of angiotensin converting enzyme inhibitors (ACEIs) [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0119775.ref022" ref-type="bibr">22</xref>], diuretics, and/or beta-blockers [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>] as their comparison group. Furthermore, to determine whether any study had particularly strong influence over the findings, such as due to assessed study quality, a leave-one-out approach was also engaged.</p>
<p>Furthermore, possible publication bias was considered using Egger’s linear regression test [<xref rid="pone.0119775.ref030" ref-type="bibr">30</xref>] and the Begg’s rank correlation test [<xref rid="pone.0119775.ref031" ref-type="bibr">31</xref>]. All statistical tests were conducted using STATA software (Version 11). A P-value less than 0.05 for any test or model was considered to be statistically significant unless otherwise indicated.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Literature search</title>
<p>Initially, 118 citations were identified. Ninety five publications were excluded after review of titles and abstracts, mainly because they did not treat cancer as the primary outcome. Full-text review was conducted for 23 studies, of which four [<xref rid="pone.0119775.ref032" ref-type="bibr">32</xref>–<xref rid="pone.0119775.ref035" ref-type="bibr">35</xref>] were excluded from the analysis because they did not refer to the association between ARB-based therapy and cancer diagnosis. Six more articles [<xref rid="pone.0119775.ref036" ref-type="bibr">36</xref>–<xref rid="pone.0119775.ref041" ref-type="bibr">41</xref>] were excluded since they did not provide all information to be extracted. Two more articles [<xref rid="pone.0119775.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0119775.ref043" ref-type="bibr">43</xref>] were excluded because they did not refer to the incidence of cancer. Moreover, one randomized controlled trial [<xref rid="pone.0119775.ref044" ref-type="bibr">44</xref>] and one animal study [<xref rid="pone.0119775.ref011" ref-type="bibr">11</xref>] were excluded. After review of the references of the remaining studies, one additional study [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>] was found to meet the inclusion criteria and was added. A total of 10 studies [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>], all published in English, were ultimately included. (<bold><xref rid="pone.0119775.g001" ref-type="fig">Fig. 1</xref></bold>)</p>
<fig id="pone.0119775.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow Chart of Study Selection.</title>
<p>Flow chart shows literature search for relevant studies about the association between ARB-based therapy and risk of cancer.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.g001" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec014">
<title>Eligible studies</title>
<p>The included 10 studies were published between 2009 and 2013. Three studies took place in Taiwan of China, two in the United States, two in the United Kingdom, two in Denmark, and one in the Netherlands. Seven studies enrolled only Caucasian participants and participants of the remaining three studies were of Asian background. Six studies were designed as retrospective cohort studies and four were case-control studies. At baseline, in the cohort studies, a total of 3,827,109 participants were included and 59,530 cases were detected during the follow-up period. In the case-control studies, 193,029 cases and 1,019,459 controls participated. The length of follow-up ranged from 2.9 to 7.8 years (one study [<xref rid="pone.0119775.ref017" ref-type="bibr">17</xref>] did not provide data on follow-up period). The ARB drugs used by participants included losartan, irbesartan, valsartan, eprosartan, candesartan, olmesartan, and telmisartan. Most of the studies confirmed disease status according to ICD-9, medical record review, or pathology reports. The exposure was status as an ever or current user of ARB treatment, and the comparison group was made up of non-ARB users [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>–<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0119775.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>], angiotensin converting enzyme inhibitor (ACEI) users [<xref rid="pone.0119775.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0119775.ref022" ref-type="bibr">22</xref>], or users of diuretics and/or beta-blockers [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>]. All 10 studies included adjustment for more than three variables, such as age, sex, body mass index (BMI), socioeconomic status, diagnosis of diabetes, concomitant use of medications including ACEIs, beta blockers (BB), calcium channel blockers (CCB), diuretics, or statins. The details are shown in <bold><xref rid="pone.0119775.t001" ref-type="table">Table 1</xref></bold>.</p>
<table-wrap id="pone.0119775.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of ten included studies of ARB and risk of cancer.</title></caption>
<alternatives>
<graphic id="pone.0119775.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Study</th>
<th align="left" rowspan="1" colspan="1">Location/Period</th>
<th align="left" rowspan="1" colspan="1">Follow-up (years)</th>
<th align="left" rowspan="1" colspan="1">Comparison</th>
<th align="left" rowspan="1" colspan="1">Type of ARB</th>
<th align="left" rowspan="1" colspan="1">Number of sample</th>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">Sites of cancer<xref rid="t001fn002" ref-type="table-fn">*</xref></th>
<th align="left" rowspan="1" colspan="1">Adjustments</th>
<th align="left" rowspan="1" colspan="1">Study conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Cohort studies</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Total of sample</td>
<td align="left" rowspan="1" colspan="1">Number of patients</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rao GA, 2013 [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>]</td>
<td align="left" rowspan="1" colspan="1">USA/1999–2010</td>
<td align="left" rowspan="1" colspan="1">4.5</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Losartan, irbesartan, valsartan, candesartan, olmesartan, telmisartan</td>
<td align="left" rowspan="1" colspan="1">1228960</td>
<td align="left" rowspan="1" colspan="1">6923</td>
<td align="left" rowspan="1" colspan="1">Lung</td>
<td align="left" rowspan="1" colspan="1">Age, race, smoking, BMI, DM</td>
<td align="left" rowspan="1" colspan="1">HR: 0.74, 95% CI: [0.67, 0.83]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rao GA, 2013 [<xref rid="pone.0119775.ref017" ref-type="bibr">17</xref>]</td>
<td align="left" rowspan="1" colspan="1">USA/2003–2009</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Losartan, irbesartan, valsartan, candesartan, olmesartan, telmisartan</td>
<td align="left" rowspan="1" colspan="1">543824</td>
<td align="left" rowspan="1" colspan="1">8775</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">Age, race, smoking, BMI, DM</td>
<td align="left" rowspan="1" colspan="1">HR: 0.91, 95% CI: [0.84, 0.99]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wang KL, 2013 [<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>]</td>
<td align="left" rowspan="1" colspan="1">Taiwan of China/1997–2009</td>
<td align="left" rowspan="1" colspan="1">4.8</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Valsartan, losartan, irbesartan, telmisartan, candesartan, olmesartan</td>
<td align="left" rowspan="1" colspan="1">85842</td>
<td align="left" rowspan="1" colspan="1">4394</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Concomitant medication including ACEI, BB, CCB, diuretics, statin, and tumor markers.</td>
<td align="left" rowspan="1" colspan="1">The cumulative incidence of cancer was 4% (ARB users) and 6% (ARB nonusers) (HR: 0.58, 95% CI [0.55, 0.62])</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pasternak B, 2011 [<xref rid="pone.0119775.ref022" ref-type="bibr">22</xref>]</td>
<td align="left" rowspan="1" colspan="1">Denmark/1998–2006</td>
<td align="left" rowspan="1" colspan="1">2.9</td>
<td align="left" rowspan="1" colspan="1">ACEI user</td>
<td align="left" rowspan="1" colspan="1">Losartan,eprosartan, valsartan, irbesartan, candesartan, telmisartan, olmesartan</td>
<td align="left" rowspan="1" colspan="1">317158</td>
<td align="left" rowspan="1" colspan="1">10168</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Calendar year, age in 5-year intervals, sex, socioeconomic class, degree of urbanization, number of hospitalizations in the previous 3 years, Charlson comorbidity index, and use of other antihypertensives (BB, thiazides, CCB)</td>
<td align="left" rowspan="1" colspan="1">RR: 0.99, 95% CI: [0.95, 1.03]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Huang CC, 2011 [<xref rid="pone.0119775.ref023" ref-type="bibr">23</xref>]</td>
<td align="left" rowspan="1" colspan="1">Taiwan of China/1995–2002</td>
<td align="left" rowspan="1" colspan="1">5.7</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Losartan, valsartan, irbesartan, candesartan, telmisartan</td>
<td align="left" rowspan="1" colspan="1">109002</td>
<td align="left" rowspan="1" colspan="1">9067</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Age, gender, DM, coronary artery disease, hyperlipidemia, heart failure, valvular heart disease, ischemic stroke, chronic renal disease, and concomitant antihypertensive agents</td>
<td align="left" rowspan="1" colspan="1">HR: 0.66, 95% CI: [0.63, 0.68]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bhaskaran K, 2012 [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>]</td>
<td align="left" rowspan="1" colspan="1">UK/1995–2010</td>
<td align="left" rowspan="1" colspan="1">4.6</td>
<td align="left" rowspan="1" colspan="1">ACEI user</td>
<td align="left" rowspan="1" colspan="1">Losartan, eprosartan, valsartan, irbesartan, candesartan, telmisartan, olmesartan</td>
<td align="left" rowspan="1" colspan="1">1542323</td>
<td align="left" rowspan="1" colspan="1">20203</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Age, sex, BMI, smoking, alcohol, DM, hypertension, heart failure, statin use, index of multiple deprivation score, calendar year</td>
<td align="left" rowspan="1" colspan="1">HR: 1.03, 95% CI: [0.99, 1.06]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Case-control studies</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Number of control</td>
<td align="left" rowspan="1" colspan="1">Number of case</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Azoulay L, 2012 [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>]</td>
<td align="left" rowspan="1" colspan="1">UK/1995–2008</td>
<td align="left" rowspan="1" colspan="1">6.4</td>
<td align="left" rowspan="1" colspan="1">Diuretics and/or beta-blockers</td>
<td align="left" rowspan="1" colspan="1">Losartan, eprosartan, valsartan, irbesartan, candesartan, telmisartan, olmesartan</td>
<td align="left" rowspan="1" colspan="1">410167</td>
<td align="left" rowspan="1" colspan="1">41059</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Excessive alcohol use, BMI, smoking, diabetes, previous cancer, and ever of aspirin, statins, and NSAIDs</td>
<td align="left" rowspan="1" colspan="1">RR: 1.00, 95% CI: [0.96, 1.03]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hallas J, 2012 [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>]</td>
<td align="left" rowspan="1" colspan="1">Denmark/2000–2005</td>
<td align="left" rowspan="1" colspan="1">7.8</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Losartan, eprosartan, valsartan, irbesartan, candesartan, telmisartan, olmesartan</td>
<td align="left" rowspan="1" colspan="1">597668</td>
<td align="left" rowspan="1" colspan="1">149417</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">RR: 1.12, 95% CI: [1.06, 1.18]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chang CH, 2011 [<xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>]</td>
<td align="left" rowspan="1" colspan="1">Taiwan of China/2000</td>
<td align="left" rowspan="1" colspan="1">7.4</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">Losartan, valsartan, irbesartan, candesartan, telmisartan</td>
<td align="left" rowspan="1" colspan="1">5104</td>
<td align="left" rowspan="1" colspan="1">1281</td>
<td align="left" rowspan="1" colspan="1">All</td>
<td align="left" rowspan="1" colspan="1">Antihypertensive agents, fast-acting human insulins, chronic liver disease, biguanides, nephropathy, glinides, retinopathy, cardiovascular disease, statins, and socioeconomic status</td>
<td align="left" rowspan="1" colspan="1">RR: 0.94, 95% CI: [0.80, 1.10]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Koomen ER, 2009 [<xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>]</td>
<td align="left" rowspan="1" colspan="1">Netherlands/1991–2004</td>
<td align="left" rowspan="1" colspan="1">3.0</td>
<td align="left" rowspan="1" colspan="1">Never using ARB</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">6520</td>
<td align="left" rowspan="1" colspan="1">1272</td>
<td align="left" rowspan="1" colspan="1">Melanoma</td>
<td align="left" rowspan="1" colspan="1">The total number of unique medical diagnoses and the use of statins</td>
<td align="left" rowspan="1" colspan="1">RR: 1.00, 95% CI: [0.70, 1.50]</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>ARB: angiotensin receptor blocker; ACEI: angiotensin-converting enzyme inhibitor; BB: beta-blocker; BMI: body mass index; CCB: calcium channel blocker; HR: hazard ratio; RR: rate ratio; NA: not available; NSAIDs: Non-steroidal anti-inflammatory drugs; UK, United Kingdom; USA: United States of America; DM: diabetes mellitus.</p></fn>
<fn id="t001fn002"><p>*All includes breast, colon, liver, lung, rectum, stomach, prostate and haematological.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>After quality assessment using the NOS, two studies [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>] received six stars; three studies [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>–<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>] received seven stars; three studies [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0119775.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0119775.ref023" ref-type="bibr">23</xref>] received eight stars; and two studies [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>] received nine stars (<bold><xref rid="pone.0119775.t002" ref-type="table">Table 2</xref></bold>).</p>
<table-wrap id="pone.0119775.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.t002</object-id>
<label>Table 2</label> <caption><title>Newcastle-Ottawa-Scale scores for the quality assessment of including studies.</title></caption>
<alternatives>
<graphic id="pone.0119775.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Studies</th>
<th align="left" rowspan="1" colspan="1">Selection</th>
<th align="left" rowspan="1" colspan="1">Comparability</th>
<th align="left" rowspan="1" colspan="1">Outcome</th>
<th align="left" rowspan="1" colspan="1">Total stars</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Cohort studies</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rao GA, 2013 [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>7</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rao GA, 2013 [<xref rid="pone.0119775.ref017" ref-type="bibr">17</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>7</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wang KL, 2013 [<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>7</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pasternak B, 2011 [<xref rid="pone.0119775.ref022" ref-type="bibr">22</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>8</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Huang CC, 2011 [<xref rid="pone.0119775.ref023" ref-type="bibr">23</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>8</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bhaskaran K, 2012 [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★★</td>
<td align="left" rowspan="1" colspan="1"><bold>9</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Case-control studies</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Azoulay L, 2012 [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>8</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hallas J, 2012 [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>6</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chang CH, 2011 [<xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1">★★★</td>
<td align="left" rowspan="1" colspan="1"><bold>9</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Koomen ER, 2009 [<xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>]</td>
<td align="left" rowspan="1" colspan="1">★★★</td>
<td align="left" rowspan="1" colspan="1">★</td>
<td align="left" rowspan="1" colspan="1">★★</td>
<td align="left" rowspan="1" colspan="1"><bold>6</bold></td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec015">
<title>ARB-based therapy and risk of cancer</title>
<sec id="sec016">
<title>Overall analysis</title>
<p>Based on the combined results of the 10 cohort studies, compared with non-ARB users or ACEI users, the patients reporting ever or current use of ARB-based therapy did not experience significantly increased risk of cancer (RR = 0.87, 95%CI: [0.75, 1.01], P = 0.07) under the random effects model (Heterogeneity: I<sup>2</sup> = 98.6%). (<bold><xref rid="pone.0119775.g002" ref-type="fig">Fig. 2</xref></bold>)</p>
<fig id="pone.0119775.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot of ARB-based therapy and risk of cancer.</title>
<p>Forest plot shows association between ARB-based therapy and risk of cancer. CI = confidence interval; ES = estimates.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.g002" position="float" xlink:type="simple"/>
</fig>
<p>Using the results of the six cohort studies, it was shown that ARB-based therapy was associated with decreased risk of cancer (RR = 0.80, 95%CI: [0.55, 0.95], P = 0.03, I<sup>2</sup> = 99.1%). However, upon analysis of the results from the four case-control studies, no significant association was found (RR = 1.03, 95%CI: [0.93, 1.13], P = 0.60, I<sup>2</sup> = 79.1%). (<bold><xref rid="pone.0119775.t003" ref-type="table">Table 3</xref></bold>)</p>
<table-wrap id="pone.0119775.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.t003</object-id>
<label>Table 3</label> <caption><title>Subgroup analyses of the included studies.</title></caption>
<alternatives>
<graphic id="pone.0119775.t003g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.t003" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">No. of studies</th>
<th align="left" rowspan="1" colspan="1">OR(95%CI)</th>
<th align="left" rowspan="1" colspan="1">P</th>
<th align="left" rowspan="1" colspan="1">I<sup>2</sup></th>
<th align="left" rowspan="1" colspan="1">Publication bias</th>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">Effect model</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Z value</td>
<td align="left" rowspan="1" colspan="1">P<sub>Begg</sub></td>
<td align="left" rowspan="1" colspan="1">t value</td>
<td align="left" rowspan="1" colspan="1">P<sub>Egger</sub></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Studies design</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cohort</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"><bold>0.80 [0.55, 0.95]</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.03</bold></td>
<td align="left" rowspan="1" colspan="1">99.1%</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
<td align="left" rowspan="1" colspan="1">0.71</td>
<td align="left" rowspan="1" colspan="1">−0.67</td>
<td align="left" rowspan="1" colspan="1">0.54</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Case-control</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.03 [0.93, 1.13]</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
<td align="left" rowspan="1" colspan="1">79.1%</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">0.73</td>
<td align="left" rowspan="1" colspan="1">−0.08</td>
<td align="left" rowspan="1" colspan="1">0.94</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Ethnicity</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Asian</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1"><bold>0.69 [0.57, 0.83]</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td>
<td align="left" rowspan="1" colspan="1">95.3%</td>
<td align="left" rowspan="1" colspan="1">0.00</td>
<td align="left" rowspan="1" colspan="1">1.00</td>
<td align="left" rowspan="1" colspan="1">0.41</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">0.97 [0.91, 1.04]</td>
<td align="left" rowspan="1" colspan="1">0.36</td>
<td align="left" rowspan="1" colspan="1">89.2%</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">0.45</td>
<td align="left" rowspan="1" colspan="1">−1.10</td>
<td align="left" rowspan="1" colspan="1">0.32</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Site of cancer</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Breast cancer</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">0.88 [0.76, 1.02]</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
<td align="left" rowspan="1" colspan="1">85.3%</td>
<td align="left" rowspan="1" colspan="1">1.80</td>
<td align="left" rowspan="1" colspan="1">0.07</td>
<td align="left" rowspan="1" colspan="1">−2.45</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lung cancer</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1"><bold>0.81 [0.69, 0.94]</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.01</bold></td>
<td align="left" rowspan="1" colspan="1">90.2%</td>
<td align="left" rowspan="1" colspan="1">0.87</td>
<td align="left" rowspan="1" colspan="1">0.39</td>
<td align="left" rowspan="1" colspan="1">−0.81</td>
<td align="left" rowspan="1" colspan="1">0.45</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Prostate cancer</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.01 [0.89, 1.12]</td>
<td align="left" rowspan="1" colspan="1">0.68</td>
<td align="left" rowspan="1" colspan="1">82.2%</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
<td align="left" rowspan="1" colspan="1">0.71</td>
<td align="left" rowspan="1" colspan="1">0.11</td>
<td align="left" rowspan="1" colspan="1">0.91</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Colorectal cancer</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.94 [0.81, 1.09]</td>
<td align="left" rowspan="1" colspan="1">0.41</td>
<td align="left" rowspan="1" colspan="1">74.0%</td>
<td align="left" rowspan="1" colspan="1">−0.24</td>
<td align="left" rowspan="1" colspan="1">1.00</td>
<td align="left" rowspan="1" colspan="1">−0.85</td>
<td align="left" rowspan="1" colspan="1">0.46</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Type of ARB</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Losartan</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.90 [0.74, 1.09]</td>
<td align="left" rowspan="1" colspan="1">0.90</td>
<td align="left" rowspan="1" colspan="1">86.7%</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">0.73</td>
<td align="left" rowspan="1" colspan="1">1.43</td>
<td align="left" rowspan="1" colspan="1">0.29</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Candesartan</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.83 [0.68, 1.01]</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
<td align="left" rowspan="1" colspan="1">80.1%</td>
<td align="left" rowspan="1" colspan="1">−0.34</td>
<td align="left" rowspan="1" colspan="1">1.00</td>
<td align="left" rowspan="1" colspan="1">7.42</td>
<td align="left" rowspan="1" colspan="1">0.02</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Irbesartan</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.89 [0.65, 1.12]</td>
<td align="left" rowspan="1" colspan="1">0.40</td>
<td align="left" rowspan="1" colspan="1">89.8%</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">0.73</td>
<td align="left" rowspan="1" colspan="1">7.58</td>
<td align="left" rowspan="1" colspan="1">0.02</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Valsartan</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.83 [0.58, 1.18]</td>
<td align="left" rowspan="1" colspan="1">0.30</td>
<td align="left" rowspan="1" colspan="1">86.2%</td>
<td align="left" rowspan="1" colspan="1">1.02</td>
<td align="left" rowspan="1" colspan="1">0.31</td>
<td align="left" rowspan="1" colspan="1">1.23</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Telmisartan</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.91 [0.59, 1.41]</td>
<td align="left" rowspan="1" colspan="1">0.78</td>
<td align="left" rowspan="1" colspan="1">86.0%</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">0.73</td>
<td align="left" rowspan="1" colspan="1">2.42</td>
<td align="left" rowspan="1" colspan="1">0.14</td>
<td align="left" rowspan="1" colspan="1">Random</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>ARB: angiotensin receptor blocker; OR: odds ratios</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec017">
<title>Subgroup analysis</title>
<p>A subgroup analysis was conducted according to participant race. For studies conducted with Asian samples, the meta-analysis revealed a significantly decreased risk of cancer among ever or current ARB users as compared to non-ARB users or ACEI users (RR = 0.69, 95%CI: [0.57, 0.83], P&lt;0.001, I<sup>2</sup> = 95.3%). In contrast, no significant associations were found in Caucasian populations (RR = 0.97, 95%CI: [0.91, 1.04], P = 0.36, I<sup>2</sup> = 89.2%). Subgroup analyses according to cancer site suggested a significant association between ARB-based therapy and decreased risk of lung cancer (RR = 0.81, 95%CI: [0.69, 0.94], P = 0.01, I<sup>2</sup> = 90.2%). However, no significant association was found in the analyses with other sites of cancer (breast: RR = 0.88, 95%CI: [0.76, 1.02], P = 0.09, I<sup>2</sup> = 85.3%; prostate: RR = 1.01, 95%CI: [0.89, 1.12], P = 0.68, I<sup>2</sup> = 82.2%; colorectal: RR = 0.94, 95%CI: [0.81, 1.09], P = 0.41, I<sup>2</sup> = 74.0%). Similarly, no association between risk of cancer and ARB use was observed upon evaluating the results of studies grouped according to ARB drug type (losartan: RR = 0.90, 95%CI: [0.74, 1.09], P = 0.29, I<sup>2</sup> = 86.7%; valsartan: RR = 0.83, 95%CI: [0.68, 1.01], P = 0.06, I<sup>2</sup> = 80.1%; irbesartan: RR = 0.89, 95%CI: [0.65, 1.12], P = 0.40, I<sup>2</sup> = 89.8%; candesartan: RR = 0.83, 95%CI: [0.58, 1.18], P = 0.30, I<sup>2</sup> = 86.2%; telmisartan: RR = 0.91, 95%CI: [0.59, 1.41], P = 0.78, I<sup>2</sup> = 86.0%). Furthermore, when we separately evaluated the studies with follow-up of at least five years, no statistically significant relationship was observed between ARB-based therapy and incidence of cancer (RR = 1.01, 95%CI: [0.95, 1.07], P = 0.80, I<sup>2</sup> = 99.1%). (<bold><xref rid="pone.0119775.t003" ref-type="table">Table 3</xref></bold>)</p>
</sec>
</sec>
<sec id="sec018">
<title>Meta-regression analysis</title>
<p>We performed meta-regression analysis to assess whether the incidence of cancer was related to ethnicity. The result showed that the incidence of cancer in ARBs users was associated with ethnicity (r = 0.37, P = 0.006, 95%CI: [−0.60, −0.14], with adjusted R-squared = 46.52%).</p>
</sec>
<sec id="sec019">
<title>Sensitivity analysis</title>
<p>Sensitivity analyses were performed to consider the influence of various exclusion criteria and to identify potential sources of heterogeneity in the association between use of ARB-based therapy and risk of cancer. Exclusion of studies with less than four years of follow up produced a pooled RR of 0.84 (95%CI: [0.69, 1.02], P = 0.08, I<sup>2</sup> = 99.0%). A sensitivity analysis excluding studies with NOS scores of six stars or less led to a pooled RR of 0.83 (95%CI: [0.71, 0.99], P = 0.03, I<sup>2</sup> = 98.8%). Removing studies with under 2000 cases produced a pooled RR of 0.85 (95%CI: [0.72, 1.01], P = 0.06, I<sup>2</sup> = 98.9%), and restricting the analysis to studies including non-ARB users as the comparison group yielded a pooled RR of 0.82 (95%CI: [0.66, 1.02], P = 0.08, I<sup>2</sup> = 98.4%). Finally, the pooled RR was 0.83 (95%CI: [0.71, 0.99], P = 0.03, I<sup>2</sup> = 98.8%) when we removed the studies with insufficient confounders [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0119775.ref024" ref-type="bibr">24</xref>].</p>
<p>Furthermore, the leave one out procedure did not alter our conclusions with overall combined RR subsequently ranging from 0.85 (95% CI: [0.72, 0.99], P = 0.04, I<sup>2</sup> = 98.6%) to 0.91 (95% CI: [0.80, 1.05], P = 0.21, I<sup>2</sup> = 98.1%).</p>
</sec>
<sec id="sec020">
<title>Publication bias</title>
<p>A funnel plot (<bold><xref rid="pone.0119775.g003" ref-type="fig">Fig. 3</xref>)</bold> was produced to determine whether significant publication bias was present. The relatively symmetrical shape of the plot was interpreted as a lack of significant publication bias. The results of the Begg’s rank correlation test and Egger’s linear regression test further indicated that there was no obvious publication bias among the included studies (<italic>P</italic><sub>Begg</sub> = 0.53, <italic>P</italic><sub>Egger</sub> = 0.74).</p>
<fig id="pone.0119775.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119775.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Funnel plot of ARB-based therapy and risk of cancer.</title>
<p>Funnel plot is relatively symmetrical which suggests there is no significant publication bias.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119775.g003" position="float" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Discussion</title>
<p>The overall results of the present study suggested that patients with a history of using ARB-based therapy were not at increased risk of cancer as compared to both patients with no history of ARB use and those who used ACEIs. However, when a subgroup analysis was conducted according to cancer site, it was observed that reduced incidence of lung cancer may be associated with ARB use. Furthermore, the combined results of included cohort studies suggested an association between ARB-based therapy and decreased risk of cancer. When the different types of ARB drugs were considered individually, no significant associations with risk of cancer were found, which was consistent with the results of analysis of 15 trials by the ARB Trialists Collaboration [<xref rid="pone.0119775.ref012" ref-type="bibr">12</xref>].</p>
<sec id="sec022">
<title>ARB-based therapy and risk of cancer</title>
<p>The relationship between ARB-based therapy and risk of cancer has drawn significant attention since 2010, when a meta-analysis of RCTs demonstrated slightly increased incidence of cancer among patients using ARBs. However, a major limitation of the study was that cancer was not the primary outcome of the included trials. Several large observational studies have since investigated the potential relationship, yet the results of individual studies have been inconsistent. Recently, Azoulay L et al [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>] showed that ARB use was not associated with increased risk of cancer relative to use of other therapies for hypertension (RR: 1.00; 95% CI: 0.96–1.03). However, ARBs were found to be associated with a small reduction in risk of colorectal cancer (adjusted RR: 0.88; 95% CI: 0.81–0.96). Rao et al showed that ARB-based therapy could decrease lung cancer incidence (HR: 0.74, 95%CI: 0.67–0.83) [<xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>] and prostate cancer incidence (HR: 0.91, 95% CI: 0.84–0.99) [<xref rid="pone.0119775.ref017" ref-type="bibr">17</xref>]. Wang et al [<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>] likewise found a protective effect with incidence of cancer being 4% among patients using ARBs and 6% among ARB nonusers (HR: 0.58, 95% CI: 0.55–0.62).</p>
<p>The present analysis investigated whether increased risk of cancer was found to be associated with ARB use based on the combined results of such observational studies. Our results suggest that patients with a history of using ARBs did not experience significantly higher incidence of breast, prostate, or colorectal cancers. In fact, a marginally reduced risk of breast cancer was observed. Furthermore, a subgroup analysis considering lung cancer cases revealed that patients reporting any ARB use had a significantly lower risk of cancer at this site. Azoulay L et al [<xref rid="pone.0119775.ref019" ref-type="bibr">19</xref>] found that the use of ACEI and calcium channel blockers was associated with 13% and 19% increasing of lung cancer, respectively; however, compared to diuretics and/or beta-blockers, use of ARBs did not increase the incidence of lung cancer. In the other included studies [<xref rid="pone.0119775.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0119775.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>], the similar conclusion was revealed. Recent laboratory studies indicated that the overexpression of angiotensin II type 2 receptor gene induced cell death in lung adenocarcinoma cells [<xref rid="pone.0119775.ref045" ref-type="bibr">45</xref>] and angiotensin-converting enzyme 2 attenuated the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition [<xref rid="pone.0119775.ref046" ref-type="bibr">46</xref>], which indirectly supported our results of subgroup analysis focusing on lung cancer.</p>
<p>Besides the popular reported sites (breast, prostate, lung or colorectal), Wang KL et al [<xref rid="pone.0119775.ref018" ref-type="bibr">18</xref>] found that ARB users may be with the lower incidence of liver (RR: 0.51, 95%CI: [0.43, 0.60]) and stomach cancer (RR: 0.61, 95%CI: [0.48, 0.78]). However, another study performed by Chang CH [<xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>] suggested that the use of ARBs was not significantly associated with the decreased incidence of liver (RR: 0.96, 95%CI: [0.64, 1.44]) and gastric cancer (RR: 0.65, 95%CI: [0.32, 1.34]) in diabetic patients. For other cancers, several studies revealed no significant association between the use of ARBs and haemotological (RR: 0.94, 95%CI: [0.74, 1.20]) [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>], tobacco related malignancies (RR: 1.08, 95%CI: [0.97, 1.20]) [<xref rid="pone.0119775.ref020" ref-type="bibr">20</xref>], or pancreatic cancer (RR: 0.68, 95%CI: [0.14, 3.21]) [<xref rid="pone.0119775.ref021" ref-type="bibr">21</xref>]. Those sites of cancer should be also paid attention, which need more data to get stronger evidence.</p>
</sec>
<sec id="sec023">
<title>Sources of heterogeneity</title>
<p>Between-study heterogeneity was assessed using the criteria of <italic>P</italic> ≤ 0.10 and I<sup>2</sup> ≥ 50% for Cochran’s <italic>χ</italic><sup>2</sup>-based Q test and the I-squared test, respectively. Due to the heterogeneity observed among included studies, pooled estimates were calculated by the random effects model for both the overall analysis and for several of the subgroup analyses. This model assumes that underlying true effects differ between studies. Sources of heterogeneity could include differences in participant characteristics across studies, study design factors, and variations in the metrics (RR versus HR) used to measure the outcome. For the present study, the use of the random effects model was expected to adequately address heterogeneity due to the lack of observable publication bias in our study. Additionally, through the sensitivity analysis, no study was found to significantly contribute to the heterogeneity; we also found no significant potential publication bias.</p>
</sec>
<sec id="sec024">
<title>Study strength and limitations</title>
<p>To the best of the author’s knowledge, this is the first meta-analysis of observational studies exploring the relationship between use of ARBs and risk of cancer. The results of the present analysis are intended to provide more robust evidence than any individual study; however, several limitations may still influence the findings. First, considerable heterogeneity was observed among the included studies. As indicated above, we used the random effects model to address the heterogeneity and conducted a sensitivity analysis to identify studies that contributed to it. Next, subgroup analyses by cancer site were only conducted for breast, prostate, colorectal, and lung cancers due to the limited evidence available for other sites. Lastly, our analysis was restricted to studies published in English or Chinese.</p>
</sec>
<sec id="sec025">
<title>Suggestion for further studies</title>
<p>Future studies should consider the association between ARB use and other cancer sites, including gastric cancer, and additional focus should be given to the rates of lung and breast cancers among ARB users.</p>
</sec>
</sec>
<sec id="sec026" sec-type="conclusions">
<title>Conclusions</title>
<p>This meta-analysis suggested that ARB-based therapy was not associated with increased risk of cancer. In contrast, use of ARBs may be related to decreased incidence of lung cancer. This conclusion should be considered carefully and confirmed with further studies.</p>
</sec>
<sec id="sec027">
<title>Supporting Information</title>
<supplementary-material id="pone.0119775.s001" xlink:href="info:doi/10.1371/journal.pone.0119775.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>PRISMA 2009 Checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0119775.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sipahi</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Debanne</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Rowland</surname> <given-names>DY</given-names></name>, <name name-style="western"><surname>Simon</surname> <given-names>DI</given-names></name>, <name name-style="western"><surname>Fang</surname> <given-names>JC</given-names></name> (<year>2010</year>) <article-title>Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials</article-title>. <source>Lancet Oncol</source> <volume>11</volume>: <fpage>627</fpage>–<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(10)70106-6" xlink:type="simple">10.1016/S1470-2045(10)70106-6</ext-link></comment> <object-id pub-id-type="pmid">20542468</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bangalore</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kjeldsen</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Makani</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Grossman</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Wetterslev</surname> <given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials</article-title>. <source>Lancet Oncol</source> <volume>12</volume>: <fpage>65</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(10)70260-6" xlink:type="simple">10.1016/S1470-2045(10)70260-6</ext-link></comment> <object-id pub-id-type="pmid">21123111</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matsuyama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Funao</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kuratsukuri</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kawahito</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sano</surname> <given-names>H</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Telmisartan inhibits human urological cancer cell growth through early apoptosis</article-title>. <source>Exp Ther Med</source> <volume>1</volume>(<issue>2</issue>): <fpage>301</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">22993542</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spiegelman</surname> <given-names>BM</given-names></name> (<year>1998</year>) <article-title>PPAR-gamma: adipogenic regulator and thiazolidinedione receptor</article-title>. <source>Diabetes</source> <volume>47</volume>: <fpage>507</fpage>–<lpage>14</lpage>. <object-id pub-id-type="pmid">9568680</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Maynard</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Anshelevich</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ni</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>IC</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling</article-title>. <source>J Clin Invest</source> <volume>115</volume>(<issue>9</issue>): <fpage>2508</fpage>–<lpage>16</lpage>. <object-id pub-id-type="pmid">16138193</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wasylyk</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Hahn</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Giovane</surname> <given-names>A</given-names></name> (<year>1993</year>) <article-title>The Ets family of transcription factors</article-title>. <source>Eur J Biochem</source> <volume>211</volume>(<issue>1–2</issue>): <fpage>7</fpage>–<lpage>18</lpage>.</mixed-citation></ref>
<ref id="pone.0119775.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Page</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Robitaille</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Pouyssegur</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Richard</surname> <given-names>DE</given-names></name> (<year>2002</year>) <article-title>Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms</article-title>. <source>J Biol Chem</source> <volume>277</volume>(<issue>50</issue>): <fpage>48403</fpage>–<lpage>09</lpage>. <object-id pub-id-type="pmid">12379645</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kosaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Miyajima</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Shirotake</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kikuchi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hasegawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mikami</surname> <given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer</article-title>. <source>Prostate</source> <volume>70</volume>(<issue>2</issue>): <fpage>162</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.21049" xlink:type="simple">10.1002/pros.21049</ext-link></comment> <object-id pub-id-type="pmid">19760626</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kinoshita</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Fushida</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Harada</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yagi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Fujita</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kinami</surname> <given-names>S</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin</article-title>. <source>Int J Oncol</source> <volume>34</volume>(<issue>6</issue>): <fpage>1573</fpage>–<lpage>82</lpage>. <object-id pub-id-type="pmid">19424575</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deshayes</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Nahmias</surname> <given-names>C</given-names></name> (<year>2005</year>) <article-title>Angiotensin receptors: a new role in cancer?</article-title> <source>Trends Endocrinol Metab</source> <volume>16</volume>: <fpage>293</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">16061390</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujita</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hayashi</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Yamashina</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fukamizu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Itoman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Majima</surname> <given-names>M</given-names></name> (<year>2005</year>) <article-title>Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth</article-title>. <source>Carcinogenesis</source> <volume>26</volume>(<issue>2</issue>): <fpage>271</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">15637093</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">ARB Trialists Collaboration</collab> (<year>2011</year>) <article-title>Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals</article-title>. <source>J Hypertens</source> <volume>29</volume>(<issue>4</issue>): <fpage>623</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HJH.0b013e328344a7de" xlink:type="simple">10.1097/HJH.0b013e328344a7de</ext-link></comment> <object-id pub-id-type="pmid">21358417</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Batra</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Gopalakrishnan</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>McNeill</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Hickie</surname> <given-names>RA</given-names></name> (<year>1994</year>) <article-title>Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors</article-title>. <source>Cancer Lett</source> <volume>76</volume>(<issue>1</issue>): <fpage>19</fpage>–<lpage>24</lpage>. <object-id pub-id-type="pmid">8124662</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gallagher</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Tallant</surname> <given-names>EA</given-names></name> (<year>2004</year>) <article-title>Inhibition of human lung cancer cell growth by angiotensin-(1–7)</article-title>. <source>Carcinogenesis</source> <volume>25</volume>(<issue>11</issue>): <fpage>2045</fpage>–<lpage>52</lpage> <object-id pub-id-type="pmid">15284177</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhaskaran</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Douglas</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>van Staa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Smeeth</surname> <given-names>L</given-names></name> (<year>2012</year>) <article-title>Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database</article-title>. <source>BMJ</source> <volume>344</volume>: <fpage>e2697</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.e2697" xlink:type="simple">10.1136/bmj.e2697</ext-link></comment> <object-id pub-id-type="pmid">22531797</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rao</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Mann</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Shoaibi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Pai</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Bottai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sutton</surname> <given-names>SS</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Angiotensin receptor blockers: are they related to lung cancer?</article-title> <source>J Hypertens</source> <volume>31</volume>(<issue>8</issue>):<fpage>1669</fpage>–<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HJH.0b013e3283621ea3" xlink:type="simple">10.1097/HJH.0b013e3283621ea3</ext-link></comment> <object-id pub-id-type="pmid">23822929</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rao</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Mann</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Bottai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Uemura</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Burch</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>CL</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Angiotensin receptor blockers and risk of prostate cancer among United States veterans</article-title>. <source>J Clin Pharmacol</source> <volume>53</volume>(<issue>7</issue>): <fpage>773</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcph.98" xlink:type="simple">10.1002/jcph.98</ext-link></comment> <object-id pub-id-type="pmid">23686462</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Chao</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>TJ</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis</article-title>. <source>Int J Cardiol</source> <volume>167</volume>(<issue>5</issue>): <fpage>2162</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2012.05.096" xlink:type="simple">10.1016/j.ijcard.2012.05.096</ext-link></comment> <object-id pub-id-type="pmid">22709730</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Azoulay</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Assimes</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Yin</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bartels</surname> <given-names>DB</given-names></name>, <name name-style="western"><surname>Schiffrin</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Suissa</surname> <given-names>S</given-names></name> (<year>2012</year>) <article-title>Long-term use of angiotensin receptor blockers and the risk of cancer</article-title>. <source>PLoS One</source> <volume>7</volume>(<issue>12</issue>): <fpage>e50893</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0050893" xlink:type="simple">10.1371/journal.pone.0050893</ext-link></comment> <object-id pub-id-type="pmid">23251399</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hallas</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Christensen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Friis</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bjerrum</surname> <given-names>L</given-names></name> (<year>2012</year>) <article-title>Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study</article-title>. <source>Br J Clin Pharmacol</source> <volume>74</volume>(<issue>1</issue>): <fpage>180</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2125.2012.04170.x" xlink:type="simple">10.1111/j.1365-2125.2012.04170.x</ext-link></comment> <object-id pub-id-type="pmid">22243442</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>MS</given-names></name> (<year>2011</year>) <article-title>Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study</article-title>. <source>J Clin Oncol</source> <volume>29</volume>(<issue>22</issue>): <fpage>3001</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.35.1908" xlink:type="simple">10.1200/JCO.2011.35.1908</ext-link></comment> <object-id pub-id-type="pmid">21690476</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pasternak</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Svanström</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Callréus</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Melbye</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hviid</surname> <given-names>A</given-names></name> (<year>2011</year>) <article-title>Use of angiotensin receptor blockers and the risk of cancer</article-title>. <source>Circulation</source> <volume>123</volume>(<issue>16</issue>): <fpage>1729</fpage>–<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.110.007336" xlink:type="simple">10.1161/CIRCULATIONAHA.110.007336</ext-link></comment> <object-id pub-id-type="pmid">21482967</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YC</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>JW</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension</article-title>. <source>Am J Cardiol</source> <volume>107</volume>(<issue>7</issue>): <fpage>1028</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2010.11.026" xlink:type="simple">10.1016/j.amjcard.2010.11.026</ext-link></comment> <object-id pub-id-type="pmid">21256465</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koomen</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Herings</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Guchelaar</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Nijsten</surname> <given-names>T</given-names></name> (<year>2009</year>) <article-title>Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</article-title>. <source>Cancer Epidemiol</source> <volume>33</volume>(<issue>5</issue>): <fpage>391</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canep.2009.10.005" xlink:type="simple">10.1016/j.canep.2009.10.005</ext-link></comment> <object-id pub-id-type="pmid">19896919</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>; <collab xlink:type="simple">PRISMA Group</collab> (<year>2009</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS Med</source> <volume>6</volume>(<issue>7</issue>): <fpage>e1000097</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000097" xlink:type="simple">10.1371/journal.pmed.1000097</ext-link></comment> <object-id pub-id-type="pmid">19621072</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref026"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm" xlink:type="simple">http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm</ext-link> [cited August 30, 2013].</mixed-citation></ref>
<ref id="pone.0119775.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hamling</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Weitkunat</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ambuhl</surname> <given-names>M</given-names></name> (<year>2008</year>) <article-title>Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category</article-title>. <source>Statist Med</source> <volume>27</volume>: <fpage>954</fpage>–<lpage>70</lpage>.</mixed-citation></ref>
<ref id="pone.0119775.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name> (<year>2002</year>) <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <volume>21</volume>:<fpage>1539</fpage>–<lpage>58</lpage>. <object-id pub-id-type="pmid">12111919</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Overton</surname> <given-names>Randall C</given-names></name> (<year>1998</year>) <article-title>A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects</article-title>. <source>Psychol Methods</source> <volume>3</volume>(<issue>3</issue>): <fpage>354</fpage>–<lpage>79</lpage>.</mixed-citation></ref>
<ref id="pone.0119775.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey</surname> <given-names>Smith G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Isayama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ijichi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Takahara</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ito</surname> <given-names>Y</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2</article-title>. <source>Invest New Drugs</source> <volume>31</volume>(<issue>5</issue>): <fpage>1294</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10637-013-9972-5" xlink:type="simple">10.1007/s10637-013-9972-5</ext-link></comment> <object-id pub-id-type="pmid">23690239</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Isayama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ijichi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kogure</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yagioka</surname> <given-names>H</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1</article-title>. <source>Cancer Sci</source> <volume>103</volume>(<issue>8</issue>): <fpage>1489</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1349-7006.2012.02311.x" xlink:type="simple">10.1111/j.1349-7006.2012.02311.x</ext-link></comment> <object-id pub-id-type="pmid">22515232</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Isayama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ijichi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sasahira</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hirano</surname> <given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine</article-title>. <source>Br J Cancer</source> <volume>103</volume>(<issue>11</issue>):<fpage>1644</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.bjc.6605955" xlink:type="simple">10.1038/sj.bjc.6605955</ext-link></comment> <object-id pub-id-type="pmid">20978506</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilop</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>von Hobe</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Crysandt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Esser</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Osieka</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Jost</surname> <given-names>E</given-names></name> (<year>2009</year>) <article-title>Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy</article-title>. <source>J Cancer Res Clin Oncol</source> <volume>135</volume>(<issue>10</issue>): <fpage>1429</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00432-009-0587-3" xlink:type="simple">10.1007/s00432-009-0587-3</ext-link></comment> <object-id pub-id-type="pmid">19399518</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sørensen</surname> <given-names>GV</given-names></name>, <name name-style="western"><surname>Ganz</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Cole</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Pedersen</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Sørensen</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Cronin-Fenton</surname> <given-names>DP</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study</article-title>. <source>J Clin Oncol</source> <volume>31</volume>(<issue>18</issue>): <fpage>2265</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2012.43.9190" xlink:type="simple">10.1200/JCO.2012.43.9190</ext-link></comment> <object-id pub-id-type="pmid">23650417</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chin</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Goo</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Noh</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>JT</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis</article-title>. <source>J Korean Med Sci</source> <volume>26</volume>(<issue>1</issue>): <fpage>59</fpage>–<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3346/jkms.2011.26.1.59" xlink:type="simple">10.3346/jkms.2011.26.1.59</ext-link></comment> <object-id pub-id-type="pmid">21218031</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>SW</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?</article-title>. <source>Oncology</source> <volume>83</volume>(<issue>6</issue>): <fpage>354</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000337979" xlink:type="simple">10.1159/000337979</ext-link></comment> <object-id pub-id-type="pmid">23052034</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yuge</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Miyajima</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Shirotake</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kosaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kikuchi</surname> <given-names>E</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer</article-title>. <source>Ann Surg Oncol</source> <volume>19</volume>(<issue>12</issue>): <fpage>3987</fpage>–<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-012-2568-z" xlink:type="simple">10.1245/s10434-012-2568-z</ext-link></comment> <object-id pub-id-type="pmid">22872290</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Makar</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Holmes</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>YX</given-names></name> (<year>2014</year>) <article-title>Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk</article-title>. <source>J Natl Cancer Inst</source> <volume>106</volume>(<issue>2</issue>): <fpage>djt374</fpage>.</mixed-citation></ref>
<ref id="pone.0119775.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chiang</surname> <given-names>YY</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>WC</given-names></name> (<year>2014</year>) <article-title>Lowered cancer risk with ace inhibitors/ARBs: a population-based cohort study</article-title>. <source>J Clin Hypertens (Greenwich)</source> <volume>16</volume>(<issue>1</issue>): <fpage>27</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jch.12228" xlink:type="simple">10.1111/jch.12228</ext-link></comment> <object-id pub-id-type="pmid">24304931</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoon</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Telli</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Kao</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Matsuda</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Carlson</surname> <given-names>RW</given-names></name>, <name name-style="western"><surname>Witteles</surname> <given-names>RM</given-names></name> (<year>2010</year>) <article-title>Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?</article-title> <source>J Am Coll Cardiol</source> <volume>56</volume>(<issue>20</issue>): <fpage>1644</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2010.07.023" xlink:type="simple">10.1016/j.jacc.2010.07.023</ext-link></comment> <object-id pub-id-type="pmid">21050974</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yilmaz</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Carrero</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Martín-Ventura</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Sonmez</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Saglam</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Celik</surname> <given-names>T</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation</article-title>. <source>Clin J Am Soc Nephrol</source> <volume>5</volume>(<issue>7</issue>): <fpage>1174</fpage>–<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.01110210" xlink:type="simple">10.2215/CJN.01110210</ext-link></comment> <object-id pub-id-type="pmid">20430947</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sugiura</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ogawa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Oka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Koyanagi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hagiwara</surname> <given-names>N</given-names></name>; <collab xlink:type="simple">HIJ-CREATE Investigators</collab> (<year>2012</year>) <article-title>Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy)</article-title>. <source>Am J Cardiol</source> <volume>109</volume>(<issue>4</issue>): <fpage>576</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2011.09.050" xlink:type="simple">10.1016/j.amjcard.2011.09.050</ext-link></comment> <object-id pub-id-type="pmid">22100194</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pickel</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Matsuzuka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Doi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ayuzawa</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Maurya</surname> <given-names>DK</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>SX</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells</article-title>. <source>Cancer Biol Ther</source> <volume>9</volume>(<issue>4</issue>): <fpage>277</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/cbt.9.4.10643" xlink:type="simple">10.4161/cbt.9.4.10643</ext-link></comment> <object-id pub-id-type="pmid">20026904</object-id></mixed-citation></ref>
<ref id="pone.0119775.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qian</surname> <given-names>YR</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wan</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Fan</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Feng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ni</surname> <given-names>L</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition</article-title>. <source>Oncol Rep</source> <volume>29</volume>(<issue>6</issue>): <fpage>2408</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/or.2013.2370" xlink:type="simple">10.3892/or.2013.2370</ext-link></comment> <object-id pub-id-type="pmid">23545945</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>